FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of immunology and biotechnology. Claimed is monoclonal antibody or its functional fragment, where said antibody and fragment bind with activated protein C and inhibit anticoagulant activity, but do not bind and do not inhibit activation of inactivated protein C, where said antibody is obtained by immunisation of mammal by APC and screening of binding ability of said antibody with APC, but not with protein C. Also described is pharmaceutical composition for treating diseases associated with anticoagulation activity of APC, including said antibody in effective amount and pharmaceutically acceptable carrier. Claimed are: method of inhibiting anticoagulation activity of activated protein C in subject, method of inhibiting amidolytic activity of activated protein C in subject, method of treating subject, requiring blood coagulation; method of treating subject with haemophilia; method of modulating haemostasis in subject; as well as method of modulating thrombogenesis in subject, which include introduction of effective quality of said antibody to subject. In addition, described is method of treating subject with sepsis, including introduction of effective quality of said antibody and activated protein C.
EFFECT: invention makes it possible to obtain monoclonal antibody or its functional fragment, where said antibody and fragment bind with activated protein C and inhibit anticoagulation activity, but do not bind and do not inhibit activation of inactivated protein C.
17 cl, 11 dwg, 6 ex
Title | Year | Author | Number |
---|---|---|---|
MONOCLONAL ANTIBODY TO ACTIVATED PROTEIN FROM HUMAN AND PRODUCTION AND USE THEREOF | 2021 |
|
RU2824515C1 |
BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
CULTIVATED HYBRID CELL STRAIN OF MOUSE Sp2/0Ag14-SpBcG/APC-15/A3 - PRODUCER OF MONOCLONAL ANTIBODIES SPECIFIC TO HUMAN PROTEIN C, MONOCLONAL ANTIBODY SPECIFIC TO HUMAN PROTEIN C AND IMMUNOSORBENT FOR HUMAN PROTEIN C SORPTION CONTAINING MONOCLONAL ANTIBODY | 2011 |
|
RU2455360C1 |
HUMANIZED ANTIBODIES SPECIFIC TO ALPHA-ENOLASE AND METHODS FOR USE IN ANTITUMOR THERAPY | 2014 |
|
RU2761662C2 |
METHODS AND COMPOSITIONS FOR IMPROVING EFFECTIVENESS OF ANTIBODY FOR MEDICAL APPLICATION WITH USING COMPOUNDS POTENTIATING NK-CELLS | 2004 |
|
RU2396981C2 |
NOVEL ANTIBODY FOR DIAGNOSIS AND/OR PROGNOSIS OF CANCER | 2011 |
|
RU2651513C2 |
METHOD OF TREATING AUTOIMMUNE DISEASE (VERSIONS) | 2009 |
|
RU2539110C2 |
SYSTEM AND METHOD OF OBTAINING AND STORAGE OF ACTIVATED MATURE DENDRITIC CELLS | 2011 |
|
RU2575978C2 |
HUMANISED ANTIBODIES TO OX40 AND METHODS FOR USE THEREOF | 2015 |
|
RU2709742C2 |
MONOCLONAL ANTIBODY, WHICH HAS IMMUNOSUPRESSIVE ACTIVITY, OR ITS ANTIGEN-BINDING FRAGMENT | 2011 |
|
RU2559550C2 |
Authors
Dates
2015-01-27—Published
2008-10-24—Filed